Despite there being an unmet need for new, non-surgical treatment options because many people have an inadequate response to current therapies or they stop working, the organisation said there is considerable uncertainty about the cost-effectiveness estimates for the drug.
NICE said that it already recommends several treatment options for when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
If approved, Stelara would be used when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment…
